Who Exports Bhasma from India — 76 Suppliers Behind a $414.6K Market
India's bhasma export market is supplied by 76 active exporters who collectively shipped $414.6K across 720 shipments. AJANTA PHARMA LIMITED leads with a 17.8% market share, followed by SHREE DHOOTAPAPESHWAR LIMITED and PATANJALI AYURVED LIMITED. The top 5 suppliers together control 56.3% of total export value, reflecting a moderately competitive market structure.
Top Bhasma Exporters from India — Ranked by Export Value
AJANTA PHARMA LIMITED is the leading bhasma exporter from India, holding a 17.8% share of the $414.6K market across 720 shipments from 76 exporters. The top 5 suppliers — AJANTA PHARMA LIMITED, SHREE DHOOTAPAPESHWAR LIMITED, PATANJALI AYURVED LIMITED, DABUR INDIA LIMITED, U SQUARE LIFESCIENCE PRIVATE LIMITED — collectively control 56.3% of total export value, indicating a moderately concentrated market. Individual shares are: AJANTA PHARMA LIMITED (17.8%), SHREE DHOOTAPAPESHWAR LIMITED (13.3%), PATANJALI AYURVED LIMITED (9.1%), DABUR INDIA LIMITED (8.2%), U SQUARE LIFESCIENCE PRIVATE LIMITED (8.0%).
Top Bhasma Exporters from India
Ranked by export value · 76 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | AJANTA PHARMA LIMITED LIVERHEAL 52 | $73.6K | 3 | 17.8% |
| 2 | SHREE DHOOTAPAPESHWAR LIMITED ASPATIC BHASMAABHRAK BHASMASUVARNA SVARNA BHASMA 100 MG | $55.1K | 2 | 13.3% |
| 3 | PATANJALI AYURVED LIMITED ASPATIC BHASMAABHRAK BHASMASUVARNA SVARNA BHASMA 100 MG | $37.8K | 1 | 9.1% |
| 4 | DABUR INDIA LIMITED ASPATIC BHASMAABHRAK BHASMASUVARNA SVARNA BHASMA 100 MG | $33.8K | 1 | 8.2% |
| 5 | U SQUARE LIFESCIENCE PRIVATE LIMITED ASPATIC BHASMAABHRAK BHASMASUVARNA SVARNA BHASMA 100 MG | $33.2K | 1 | 8.0% |
| 6 | EPSTOM SPEC CHEM PRIVATE LIMITED YASHAD BHASMA MANUFACTURING -UMA AYURVEDICS PRIVATELIMITEDYASHAD BHASMAYASHAD BHASMACREAMISH WHITE COLOURED POWDER | $23.7K | 1 | 5.7% |
| 7 | DARSHAN DRUG HOUSE PRIVATE LIMITED ASPATIC BHASMAABHRAK BHASMASUVARNA SVARNA BHASMA 100 MG | $15.3K | 1 | 3.7% |
| 8 | NIROGAM INDIA PRIVATE LIMITED SHANKH BHASMA ITEM INFO CODE - ABHN006100% NATURAL HERB EXTRACTS - SHANKH BHASMA100% NATURAL HERB EXTRACTS FOR ANIMAL FEED :- SHANKH BHASMA | $14.2K | 1 | 3.4% |
| 9 | HIMALAYA WELLNESS COMPANY YASHAD BHASMA MANUFACTURING -UMA AYURVEDICS PRIVATELIMITEDYASHAD BHASMAYASHAD BHASMACREAMISH WHITE COLOURED POWDER | $10.8K | 2 | 2.6% |
| 10 | BHARATH VAIDYASALA AYURVEDA PRODUCTS - ABHRAKABHASMAM CAPGODANTI BHASMAAYURVEDIC PRODUCTS - SHANKABHASMAM CAPNOS | $8.8K | 1 | 2.1% |
| 11 | THE ARYA VAIDYA PHARMACY COIMBATORE LIMITED YASHAD BHASMA MANUFACTURING -UMA AYURVEDICS PRIVATELIMITEDYASHAD BHASMAYASHAD BHASMACREAMISH WHITE COLOURED POWDER | $6.5K | 2 | 1.6% |
| 12 | SREE EXPORTS YASHAD BHASMA MANUFACTURING -UMA AYURVEDICS PRIVATELIMITEDYASHAD BHASMAYASHAD BHASMACREAMISH WHITE COLOURED POWDER | $5.5K | 1 | 1.3% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Bhasma exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Ajanta Pharma Limited | Not Listed | Yes, as of December | No | Not verified | WHO-GMP certified facility in Bharuch, Gujarat, India. (extranet.who.int) |
| Himalaya Drug Company | Not Listed | Yes, as of February | No | Not verified | WHO-GMP certified for products including Septilin Syrup and Bonnisan Drops. |
| Divya Pharmacy | Not Listed | Yes, as of February | No | Not verified | WHO-GMP certified for products like Divya Vatari Churna and Triphala Churna. |
| Charak Pharma Pvt. Ltd. | Not Listed | Yes, as of November | No | Not verified | WHO-GMP certified for products such as Endotone Capsule and Addyzoa Capsule. |
| Shri Kartikeya Pharma | Not Listed | Yes, as of January 2 | No | Not verified | WHO-GMP certified for Ashwagandha Churnam. |
| Indian Institute of Integrative Medicine (CSIR) | Not Listed | Yes, as of December | No | Not verified | WHO-GMP certified for Ulcrine Capsule 450 mg. |
| Albert David Limited | Not Listed | Yes, as of February | No | Not verified | WHO-GMP certified for tablets at Kolkata facility. |
| Eisai Pharmatechnology and Manufacturing Pvt. Ltd. | Not Listed | Yes, as of February | No | Not verified | WHO-GMP certified manufacturing unit in Andhra Pradesh. |
TransData Nexus reviewed the regulatory standing of 8 leading Bhasma exporters from India. 0 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 0 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Bhasma sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts over 800 pharmaceutical companies, including industry leaders such as Dr. Reddy’s Laboratories, Aurobindo Pharma, and Divi’s Laboratories. The presence of Genome Valley, India's first biotech cluster, further enhances Hyderabad's prominence in the pharmaceutical sector. This robust infrastructure and concentration of expertise make Hyderabad a significant contributor to the production of APIs used in formulations like Bhasma.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production, with major companies such as Zydus Cadila, Intas Pharmaceuticals, and Torrent Pharmaceuticals operating in this region. The state's well-developed infrastructure, including ports and transportation networks, supports efficient manufacturing and distribution. This specialization in formulations positions the Ahmedabad-Vadodara cluster as a key player in the production and export of Ayurvedic products like Bhasma.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being a major port city, facilitates the export of pharmaceutical products to various international markets. The region is home to numerous pharmaceutical companies that leverage this strategic location to distribute products globally. The proximity to major shipping ports enhances the efficiency of exporting products like Bhasma to destinations such as Nepal, the United Arab Emirates, and Kyrgyzstan.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in the Solan district of Himachal Pradesh, is recognized as Asia's largest pharmaceutical hub. The region houses over 1,000 pharmaceutical manufacturing units, including major players like Cipla, Dr. Reddy's Laboratories, and Cadila Healthcare. Baddi's prominence is attributed to favorable government policies, including tax incentives, and its strategic location near key markets. This makes Baddi a significant center for the production of various pharmaceutical products, including Ayurvedic formulations like Bhasma.
5Sourcing Recommendations
- Leverage Hyderabad's API Production: Utilize Hyderabad's extensive API manufacturing capabilities to source high-quality raw materials for Bhasma formulations.
- Engage with Ahmedabad-Vadodara Formulation Experts: Collaborate with companies in the Ahmedabad-Vadodara region to develop and manufacture Bhasma products, benefiting from their expertise in pharmaceutical formulations.
- Utilize Mumbai's Export Infrastructure: Take advantage of Mumbai's port facilities to efficiently export Bhasma products to international markets, ensuring timely delivery and compliance with global standards.
- Consider Baddi for Cost-Effective Manufacturing: Explore manufacturing opportunities in Baddi to benefit from tax incentives and a well-established pharmaceutical ecosystem, potentially reducing production costs for Bhasma products.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Bhasma exporters from India
Dabur India Limited — Dabur acquires 51% stake in Sesa Care for ₹315-325 crore
In November 2024, Dabur India Limited acquired a 51% stake in Sesa Care, an Indian haircare company, for an enterprise value of ₹315-325 crore. - IMPACT: This acquisition is expected to enhance Dabur's product portfolio, potentially increasing its Bhasma exports.
Impact: This acquisition is expected to enhance Dabur's product portfolio, potentially increasing its Bhasma exports.
Patanjali Ayurved Limited — Patanjali and DS Group acquire Magma General Insurance for ₹4,500 crore
In March 2025, Patanjali Ayurved Limited, in partnership with DS Group, acquired Magma General Insurance for ₹4,500 crore. - IMPACT: While this acquisition diversifies Patanjali's business, it may indirectly support its Bhasma export operations through enhanced financial stability.
Impact: While this acquisition diversifies Patanjali's business, it may indirectly support its Bhasma export operations through enhanced financial stability.
Patanjali Ayurved Limited — Patanjali inaugurates hybrid hospital for heart, brain, and spine care
On January 22, 2026, Patanjali Ayurved Limited opened the "Patanjali Emergency & Critical Care Hospital," India's first hybrid hospital specializing in heart, brain, and spine care. - IMPACT: This expansion into healthcare services may bolster Patanjali's brand reputation, potentially leading to increased demand for its Bhasma products.
Impact: This expansion into healthcare services may bolster Patanjali's brand reputation, potentially leading to increased demand for its Bhasma products.
Common Questions — Bhasma Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which bhasma supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, AJANTA PHARMA LIMITED leads with 27 recorded shipments worth $73.6K. SHREE DHOOTAPAPESHWAR LIMITED (123 shipments) and PATANJALI AYURVED LIMITED (14 shipments) are also established high-volume exporters.
Q How many bhasma manufacturers are there in India?
India has 76 active bhasma exporters with a combined export market of $414.6K across 720 shipments to 34 countries. The top 5 suppliers hold 56.3% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for bhasma from India?
Average FOB unit price: $10.88 per unit, ranging from $0.08 to $1452.78. Average shipment value: $576.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 76 verified Indian exporters of Bhasma ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 720 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 34 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
720 Verified Shipments
76 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists